EDIT: Editas Medicine, Inc.
Performance
EDIT +11.34%
Watchlist
Select an item
Summary
EDIT at a glance
EDIT returned +11.34% over the past year and -40.61% a year over five years. Its worst drop in that year was -39.47%, smaller than 38% of stocks on Redstone, and its Sharpe ratio of 0.49 beats 50% of stocks on Redstone. It pays no dividends.
Current Drawdown
-26.67%
Rolling Volatility
97.95%
Actions
Metrics
Risk Indicators
Alpha17.98%
Beta2.28x
Sharpe0.49
Sortino0.75
Omega1.09
Calmar0.29
Martin1.85
Profile
About EDIT
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary gene editing platform based on CRISPR technology and continues to expand its capabilities.
- Sector
- Health Care
- Industry
- Biological Products, (no Diagnostic Substances)
- Market cap
- $422M
- Listed
- Feb 2016
- Employees
- 87
- Headquarters
- Cambridge, MA
- Website
- editasmedicine.com
Comparisons